Orum Therapeutics closed a $100 million financing round to advance its pipeline of 'degrader‑antibody conjugates'—antibody vehicles that deliver protein‑degrading small molecules rather than cytotoxic payloads—with a lead program targeting CD123 in acute myeloid leukemia. The funding will support clinical advancement of ORM‑1153 and platform expansion. Orum highlighted observed liver toxicity in a prior HER2 program and refocused on hematology targets; the company also maintains partnerships with Bristol Myers Squibb and Vertex to broaden application of its platform.